Jabbour Salma K, Berman Abigail T, Simone Charles B
Department of Radiation Oncology, Rutgers Cancer Institute of New Jersey, Rutgers Robert Wood Johnson Medical School, Rutgers University, New Brunswick, NJ, USA.
Department of Radiation Oncology, Perelman School of Medicine, Hospital of the University of Pennsylvania, Philadelphia, PA, USA.
Transl Lung Cancer Res. 2017 Apr;6(2):113-118. doi: 10.21037/tlcr.2017.04.02.
For patients with inoperable stage II-III non-small cell lung cancer (NSCLC), the backbone of curative intent therapy is concurrent chemoradiotherapy (CRT). As checkpoint inhibitors have shown clinical benefit in the setting of metastatic NSCLC, additional study is necessary to understand their role in patients receiving CRT. When integrating immunotherapy with radiotherapy (RT) for cure, clinicians will need to consider synergy, timing, doses, and safety among the combination of therapies. This article seeks to review data evaluating interactions, temporal sequencing, fractionation, and overlapping toxicity profiles of thoracic chemoradiation and immunotherapy.
对于无法手术的II-III期非小细胞肺癌（NSCLC）患者，根治性治疗的主要方法是同步放化疗（CRT）。由于检查点抑制剂已在转移性NSCLC患者中显示出临床获益，因此有必要进行更多研究以了解其在接受CRT治疗的患者中的作用。当将免疫疗法与放疗（RT）联合用于根治时，临床医生需要考虑联合治疗之间的协同作用、时间安排、剂量和安全性。本文旨在综述评估胸部放化疗与免疫疗法之间相互作用、时间顺序、分割方式和重叠毒性特征的数据。
